<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946438</url>
  </required_header>
  <id_info>
    <org_study_id>GRC52</org_study_id>
    <secondary_id>U1111-1127-7587</secondary_id>
    <nct_id>NCT01946438</nct_id>
  </id_info>
  <brief_title>Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults</brief_title>
  <official_title>Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines, 2013-2014 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is describe the safety and immunogenicity of Fluzone Quadrivalent and
      Fluzone Intradermal vaccines in adults 18 to &lt; 65 years of age, and to describe the safety
      and immunogenicity of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65
      years of age.

      Primary Objective:

        -  To describe the safety of the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone
           Intradermal vaccines in adults 18 to &lt; 65 years of age and the safety of the 2013-2014
           formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in adults ≥ 65 years
           of age.

      Observational objectives:

        -  To describe the immunogenicity of the 2013-2014 formulations of Fluzone Quadrivalent and
           Fluzone Intradermal vaccines in adults 18 to &lt; 65 years of age and the immunogenicity of
           the 2013-2014 formulations of Fluzone Quadrivalent and Fluzone High-Dose vaccines in
           adults ≥ 65 years of age.

        -  To evaluate the compliance, in terms of immunogenicity, of each study vaccine (Fluzone
           Quadrivalent, Fluzone Intradermal, and Fluzone High-Dose) in the applicable age group
           with the historical requirements of the Committee for Human Medicinal Products (CHMP)
           Note for Guidance (NfG) CPMP/BWP/214/96.

        -  To submit sera from selected subjects to the Center for Biologics Evaluation and
           Research (CBER) for further analysis by the World Health Organization (WHO), the Centers
           for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to
           support formulation recommendations for subsequent influenza vaccines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants 18 to &lt; 65 years of age on enrollment will be randomized to receive either
      Fluzone Quadrivalent or Fluzone Intradermal vaccine. Participants ≥ 65 years of age at
      enrollment will be randomized to receive either Fluzone Quadrivalent or Fluzone High-Dose
      vaccine.

      Solicited adverse event (AE) information will be collected for 7 days after each vaccination,
      unsolicited AE and Serious adverse event information will be collected from Visit 1 to Visit
      2. Total duration of participation in the study is approximately 21 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine.</measure>
    <time_frame>Day 0 up to Day 21 post-vaccination</time_frame>
    <description>Solicited injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Grade 3: Pain, Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis, &gt;100 mm; Fever, ≥102.1°F; Headache, Malaise, Myalgia, and Shivering, Significant, prevents daily activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antibodies to the Antigens Contained in the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine Before and Following Vaccination With the Respective Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 after vaccination</time_frame>
    <description>Influenza virus antibodies were measured using a hemagglutination inhibition (HAI) assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Seroprotection Before and Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 after vaccination</time_frame>
    <description>Influenza virus antibodies were measured using an HAI assay. Seroprotection was defined as a titer of ≥40 (1/dilution).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Seroconversion Following Vaccination With the 2013-2014 Formulations of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination) and Day 21 after vaccination</time_frame>
    <description>Influenza virus antibodies were measured using an HAI assay. Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in titer after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer Ratios (GMTRs) of Antibodies to Antigens Contained in the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine Following Vaccination With the Respective Vaccine</measure>
    <time_frame>Day 21 after vaccination</time_frame>
    <description>Influenza virus antibodies were measured using an HAI assay. Geometric mean titer ratios are the geometric means of the individual post-vaccination/pre-vaccination titer ratios for each hemagglutinin antigen contained in the vaccines.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants age 18 to &lt; 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants age 18 to &lt; 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</arm_group_label>
    <other_name>Fluzone® Quadrivalent, Influenza Virus Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),</intervention_name>
    <description>0.1 mL, Intradermal</description>
    <arm_group_label>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</arm_group_label>
    <other_name>Fluzone® Intradermal, Influenza Virus Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</arm_group_label>
    <other_name>Fluzone® Quadrivalent, Influenza Virus Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</arm_group_label>
    <other_name>Fluzone® High-Dose, Influenza Virus Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age on the day of inclusion

          -  Informed consent form has been signed and dated

          -  Able to attend all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  History of serious adverse reaction to any influenza vaccine

          -  Receipt of any vaccine within 30 days before receiving study vaccine, or plans to
             receive another vaccine before Visit 2.

          -  Participation in another interventional clinical trial investigating a vaccine, drug,
             medical device, or medical procedure in the 30 days preceding the first study
             vaccination or during the course of the study, unless no intervention for the other
             study occurred within the 30 days prior to the first study vaccination and none are
             planned before the subject would complete safety surveillance for the present study

          -  Thrombocytopenia, which may be a contraindication for intramuscular vaccination, at
             the discretion of the Investigator

          -  Prior vaccination with any 2013-2014 formulation of influenza vaccine

          -  Known systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine
             components, or a history of a life-threatening reaction to Fluzone Quadrivalent,
             Fluzone Intradermal, or Fluzone High-Dose vaccine or to a vaccine containing any of
             the same substances (the complete list of vaccine components is included in the
             Prescribing Information)

          -  Receipt of immune globulins, blood, or blood-derived products in the past 3 months

          -  Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion,
             which may be a contraindication for intramuscular vaccination, at the discretion of
             the Investigator

          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of
             non-childbearing potential, a female must be pre-menarche or post-menopausal for at
             least 1 year, surgically sterile, or using an effective method of contraception or
             abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after
             vaccination)

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             subject if enrolled or could interfere with the evaluation of the vaccine

          -  Personal history of Guillain-Barré syndrome

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)

          -  Chronic illness that, in the opinion of the Investigator, is at a stage where it might
             interfere with trial conduct or completion

          -  Seropositivity for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, as
             reported by the subject

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily

          -  Current alcohol or drug addiction that, in the opinion of the Investigator, might
             interfere with the ability to comply with trial procedures

          -  Moderate or severe acute illness/infection (according to Investigator judgment) or
             febrile illness (temperature ≥ 100.4°F]) on the day of vaccination. A prospective
             subject should not be included in the study until the condition has resolved or the
             febrile event has subsided

          -  Identified as an Investigator or employee of the Investigator or study center with
             direct involvement in the proposed study, or identified as an immediate family member
             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with
             direct involvement in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <results_first_submitted>September 17, 2014</results_first_submitted>
  <results_first_submitted_qc>September 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 25, 2014</results_first_posted>
  <last_update_submitted>September 17, 2014</last_update_submitted>
  <last_update_submitted_qc>September 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),</keyword>
  <keyword>Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),</keyword>
  <keyword>Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 16 to 24 September 2013 at 4 clinic centers in the United States.</recruitment_details>
      <pre_assignment_details>A total of 208 participants who met all of the inclusion and none of the exclusion criteria were enrolled and vaccinated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
          <description>Participants age 18 to &lt; 65 years who received a 0.5 mL dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="P2">
          <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
          <description>Participants age 18 to &lt; 65 years who received a 0.1 mL dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
        </group>
        <group group_id="P3">
          <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
          <description>Participants age ≥ 65 years who received a 0.5 mL dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="P4">
          <title>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</title>
          <description>Participants age ≥ 65 years who received a 0.5 mL dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
          <description>Participants age 18 to &lt; 65 years who received a 0.5 mL dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="B2">
          <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
          <description>Participants age 18 to &lt; 65 years who received a 0.1 mL dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
        </group>
        <group group_id="B3">
          <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
          <description>Participants age ≥ 65 years who received a 0.5 mL dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="B4">
          <title>Elderly Fluzone® High Dose, Influenza Vaccine (Group 4)</title>
          <description>Participants age ≥ 65 years who received a 0.5 mL dose of Fluzone® High Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="208"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="15.2"/>
                    <measurement group_id="B2" value="46.9" spread="14.7"/>
                    <measurement group_id="B3" value="71.5" spread="4.7"/>
                    <measurement group_id="B4" value="72.6" spread="5.2"/>
                    <measurement group_id="B5" value="58.75" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine.</title>
        <description>Solicited injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Grade 3: Pain, Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis, &gt;100 mm; Fever, ≥102.1°F; Headache, Malaise, Myalgia, and Shivering, Significant, prevents daily activity.</description>
        <time_frame>Day 0 up to Day 21 post-vaccination</time_frame>
        <population>Solicited injection-site reactions and systemic reactions were assessed using the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O2">
            <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
          </group>
          <group group_id="O3">
            <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O4">
            <title>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Solicited Injection-Site and Solicited Systemic Reactions Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine.</title>
          <description>Solicited injection-site reactions: Pain, Erythema, Swelling, Induration, and Ecchymosis. Systemic reactions: Fever (Temperature), Headache, Malaise, Myalgia, and Shivering. Grade 3: Pain, Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis, &gt;100 mm; Fever, ≥102.1°F; Headache, Malaise, Myalgia, and Shivering, Significant, prevents daily activity.</description>
          <population>Solicited injection-site reactions and systemic reactions were assessed using the Safety Analysis Set, which includes all persons who received at least one dose of study vaccine.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection-site pain (N = 52, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="21" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site pain (N = 52, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-ste erythema (N=52,52,52,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site erythema (N =52, 52,52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site swelling (N = 51, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site swelling (N = 51,52,52,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site induration (N = 51, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site induration (N= 51,52,52,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection-site ecchymosis (N = 51, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection-site ecchymosis (N= 51,52,52,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (N = 52, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (N = 52, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (N = 52, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (N = 52, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (N = 52, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="8" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (N = 52, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (N = 52, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="16" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="6" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="10" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (N = 52, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="1" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering (N = 52, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="4" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (N = 52, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Antibodies to the Antigens Contained in the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine Before and Following Vaccination With the Respective Vaccine</title>
        <description>Influenza virus antibodies were measured using a hemagglutination inhibition (HAI) assay.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 after vaccination</time_frame>
        <population>Geometric mean titers of antibodies against the hemagglutinin (HA) antigens were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Quadrivalent, Influenza Vaccine 2013-2014 formulation</description>
          </group>
          <group group_id="O2">
            <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
          </group>
          <group group_id="O3">
            <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O4">
            <title>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Antibodies to the Antigens Contained in the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine Before and Following Vaccination With the Respective Vaccine</title>
          <description>Influenza virus antibodies were measured using a hemagglutination inhibition (HAI) assay.</description>
          <population>Geometric mean titers of antibodies against the hemagglutinin (HA) antigens were assessed in the Per-Protocol Analysis Set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" lower_limit="48.0" upper_limit="141"/>
                    <measurement group_id="O2" value="74.3" lower_limit="46.3" upper_limit="119"/>
                    <measurement group_id="O3" value="54.7" lower_limit="36.9" upper_limit="81.1"/>
                    <measurement group_id="O4" value="91.0" lower_limit="60.7" upper_limit="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="514" lower_limit="366" upper_limit="722"/>
                    <measurement group_id="O2" value="471" lower_limit="332" upper_limit="669"/>
                    <measurement group_id="O3" value="163" lower_limit="119" upper_limit="224"/>
                    <measurement group_id="O4" value="345" lower_limit="255" upper_limit="467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="45.2" upper_limit="132"/>
                    <measurement group_id="O2" value="128" lower_limit="81.2" upper_limit="203"/>
                    <measurement group_id="O3" value="185" lower_limit="128" upper_limit="267"/>
                    <measurement group_id="O4" value="104" lower_limit="67.7" upper_limit="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563" lower_limit="399" upper_limit="796"/>
                    <measurement group_id="O2" value="531" lower_limit="396" upper_limit="712"/>
                    <measurement group_id="O3" value="449" lower_limit="344" upper_limit="587"/>
                    <measurement group_id="O4" value="636" lower_limit="464" upper_limit="871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Yamagata; pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2" lower_limit="23.3" upper_limit="50.4"/>
                    <measurement group_id="O2" value="38.2" lower_limit="26.7" upper_limit="54.6"/>
                    <measurement group_id="O3" value="32.4" lower_limit="24.4" upper_limit="43.1"/>
                    <measurement group_id="O4" value="36.1" lower_limit="28.2" upper_limit="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Yamagata; post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142" lower_limit="105" upper_limit="192"/>
                    <measurement group_id="O2" value="147" lower_limit="110" upper_limit="196"/>
                    <measurement group_id="O3" value="67.5" lower_limit="55.3" upper_limit="82.4"/>
                    <measurement group_id="O4" value="122" lower_limit="98.5" upper_limit="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Victoria; pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.7" lower_limit="17.6" upper_limit="34.7"/>
                    <measurement group_id="O2" value="NA">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="34.2" lower_limit="25.8" upper_limit="45.5"/>
                    <measurement group_id="O4" value="NA">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Victoria; post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" lower_limit="96.6" upper_limit="186"/>
                    <measurement group_id="O2" value="NA">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="67.5" lower_limit="52.7" upper_limit="86.4"/>
                    <measurement group_id="O4" value="NA">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Seroprotection Before and Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine</title>
        <description>Influenza virus antibodies were measured using an HAI assay. Seroprotection was defined as a titer of ≥40 (1/dilution).</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 after vaccination</time_frame>
        <population>Seroprotection against the hemagglutinin antigens were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O2">
            <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
          </group>
          <group group_id="O3">
            <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O4">
            <title>Elderly Fluzone® High Dose, Influenza Vaccine (Group 4)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Seroprotection Before and Following Vaccination With the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine</title>
          <description>Influenza virus antibodies were measured using an HAI assay. Seroprotection was defined as a titer of ≥40 (1/dilution).</description>
          <population>Seroprotection against the hemagglutinin antigens were assessed in the Per-Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="36" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="39" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="52" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="47" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="51" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="41" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="47" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="41" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="51" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Yamagata; pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="31" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="26" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="29" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Yamagata; post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="49" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="45" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="50" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Victoria; pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="32" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Victoria; post-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="42" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Seroconversion Following Vaccination With the 2013-2014 Formulations of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine</title>
        <description>Influenza virus antibodies were measured using an HAI assay. Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in titer after vaccination.</description>
        <time_frame>Day 0 (pre-vaccination) and Day 21 after vaccination</time_frame>
        <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O2">
            <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
            <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
          </group>
          <group group_id="O3">
            <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O4">
            <title>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</title>
            <description>Participants age ≥ 65 years who received a dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Seroconversion Following Vaccination With the 2013-2014 Formulations of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine</title>
          <description>Influenza virus antibodies were measured using an HAI assay. Seroconversion was defined as either a pre-vaccination HAI titer &lt; 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and a ≥ 4-fold increase in titer after vaccination.</description>
          <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in the Per-Protocol Analysis Set.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="17" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="25" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="19" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="15" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="33" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Yamagata)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="21" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="NA" lower_limit="0" upper_limit="0">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer Ratios (GMTRs) of Antibodies to Antigens Contained in the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine Following Vaccination With the Respective Vaccine</title>
        <description>Influenza virus antibodies were measured using an HAI assay. Geometric mean titer ratios are the geometric means of the individual post-vaccination/pre-vaccination titer ratios for each hemagglutinin antigen contained in the vaccines.</description>
        <time_frame>Day 21 after vaccination</time_frame>
        <population>Geometric mean titer ratios against each hemagglutinin antigen were assessed in the Per-Protocol Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
            <description>Participants age 18 to &lt; 65 years who received a 0.5 mL dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O2">
            <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
            <description>Participants age 18 to &lt; 65 years who received a 0.1 mL dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
          </group>
          <group group_id="O3">
            <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
            <description>Participants age ≥ 65 years who received a 0.5 mL dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
          <group group_id="O4">
            <title>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</title>
            <description>Participants age ≥ 65 years who received a 0.5 mL dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios (GMTRs) of Antibodies to Antigens Contained in the 2013-2014 Formulation of Fluzone® Quadrivalent, Fluzone® Intradermal, or Fluzone® High-Dose Vaccine Following Vaccination With the Respective Vaccine</title>
          <description>Influenza virus antibodies were measured using an HAI assay. Geometric mean titer ratios are the geometric means of the individual post-vaccination/pre-vaccination titer ratios for each hemagglutinin antigen contained in the vaccines.</description>
          <population>Geometric mean titer ratios against each hemagglutinin antigen were assessed in the Per-Protocol Analysis Set.</population>
          <units>Titer Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" lower_limit="3.29" upper_limit="9.44"/>
                    <measurement group_id="O2" value="5.77" lower_limit="3.33" upper_limit="10.0"/>
                    <measurement group_id="O3" value="2.89" lower_limit="2.10" upper_limit="3.97"/>
                    <measurement group_id="O4" value="3.66" lower_limit="2.78" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" lower_limit="4.22" upper_limit="9.79"/>
                    <measurement group_id="O2" value="3.92" lower_limit="2.62" upper_limit="5.87"/>
                    <measurement group_id="O3" value="2.40" lower_limit="1.81" upper_limit="3.19"/>
                    <measurement group_id="O4" value="6.10" lower_limit="4.12" upper_limit="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Yamagata)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" lower_limit="2.56" upper_limit="5.12"/>
                    <measurement group_id="O2" value="3.50" lower_limit="2.36" upper_limit="5.18"/>
                    <measurement group_id="O3" value="1.95" lower_limit="1.64" upper_limit="2.31"/>
                    <measurement group_id="O4" value="3.28" lower_limit="2.58" upper_limit="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Victoria)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="3.23" upper_limit="6.95"/>
                    <measurement group_id="O2" value="NA">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="1.86" lower_limit="1.55" upper_limit="2.22"/>
                    <measurement group_id="O4" value="NA">B (Victoria) antigen was not in the vaccine administered to this group</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to Day 21 after vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)</title>
          <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="E2">
          <title>Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)</title>
          <description>Participants age 18 to &lt; 65 years who received a dose of Fluzone® Intradermal, Influenza Virus Vaccine intradermally (2013-2014 formulation)</description>
        </group>
        <group group_id="E3">
          <title>Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)</title>
          <description>Participants age ≥ 65 years who received a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
        <group group_id="E4">
          <title>Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)</title>
          <description>Participants age ≥ 65 years who received a dose of Fluzone® High-Dose, Influenza Virus Vaccine intramuscularly (2013-2014 formulation)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="52"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="52"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Injection-site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="52"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="52"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

